AU2021405730A1 - Anti-il1rap antibody - Google Patents

Anti-il1rap antibody Download PDF

Info

Publication number
AU2021405730A1
AU2021405730A1 AU2021405730A AU2021405730A AU2021405730A1 AU 2021405730 A1 AU2021405730 A1 AU 2021405730A1 AU 2021405730 A AU2021405730 A AU 2021405730A AU 2021405730 A AU2021405730 A AU 2021405730A AU 2021405730 A1 AU2021405730 A1 AU 2021405730A1
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen
binding fragment
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021405730A
Other languages
English (en)
Other versions
AU2021405730A9 (en
Inventor
Gabriel Svensson BIRKEDAL
Caitríona GRÖNBERG
David LIBERG
Camilla Rydberg MILLRUD
Sara RATTIK
Kjell SJÖSTRÖM
Karin Von Wachenfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Cantargia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2105933.2A external-priority patent/GB202105933D0/en
Application filed by Cantargia AB filed Critical Cantargia AB
Publication of AU2021405730A1 publication Critical patent/AU2021405730A1/en
Publication of AU2021405730A9 publication Critical patent/AU2021405730A9/en
Assigned to OTSUKA PHARMACEUTICAL CO., LTD. reassignment OTSUKA PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: CANTARGIA AB
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2021405730A 2020-12-23 2021-12-22 Anti-il1rap antibody Pending AU2021405730A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20216926.4 2020-12-23
EP20216926 2020-12-23
GBGB2105933.2A GB202105933D0 (en) 2021-04-26 2021-04-26 Anti-IL1rap antibody
GB2105933.2 2021-04-26
EP21212368 2021-12-03
EP21212368.1 2021-12-03
PCT/EP2021/087338 WO2022136569A1 (en) 2020-12-23 2021-12-22 Anti-il1rap antibody

Publications (2)

Publication Number Publication Date
AU2021405730A1 true AU2021405730A1 (en) 2023-07-06
AU2021405730A9 AU2021405730A9 (en) 2025-03-20

Family

ID=79731073

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021405730A Pending AU2021405730A1 (en) 2020-12-23 2021-12-22 Anti-il1rap antibody

Country Status (9)

Country Link
US (2) US11479610B2 (https=)
EP (1) EP4267625A1 (https=)
JP (1) JP2024500920A (https=)
KR (1) KR20230123962A (https=)
AU (1) AU2021405730A1 (https=)
CA (1) CA3202942A1 (https=)
IL (1) IL303922A (https=)
MX (1) MX2023007611A (https=)
WO (1) WO2022136569A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020035577A1 (en) 2018-08-16 2020-02-20 Cantargia Ab Anti-il1rap antibody compositions
EP4267625A1 (en) * 2020-12-23 2023-11-01 Cantargia AB Anti-il1rap antibody
CA3220913A1 (en) 2021-05-21 2022-11-24 Leo Pharma A/S Anti il-1 receptor accessory protein antibodies
AR130550A1 (es) 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso
CN116284401B (zh) * 2023-02-20 2024-09-24 中国人民解放军军事科学院军事医学研究院 人源抗il-1r3抗体及其应用
EP4705340A1 (en) 2023-05-05 2026-03-11 Otsuka Pharmaceutical Co., Ltd. Anti-il1rap antibodies
CN120775048A (zh) * 2024-04-02 2025-10-14 信达生物制药(苏州)有限公司 抗il1rap抗体以及其用途
WO2026022232A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Il-1rap inhibitor for treating or preventing hidradenitis suppurativa

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US9403906B2 (en) 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
JP7114460B2 (ja) * 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
CA3084459A1 (en) * 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
AU2018312563A1 (en) 2017-08-01 2020-03-12 City Of Hope Anti-IL1RAP antibodies
WO2020035577A1 (en) 2018-08-16 2020-02-20 Cantargia Ab Anti-il1rap antibody compositions
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
EP4267625A1 (en) * 2020-12-23 2023-11-01 Cantargia AB Anti-il1rap antibody

Also Published As

Publication number Publication date
MX2023007611A (es) 2023-07-12
CA3202942A1 (en) 2022-06-30
IL303922A (en) 2023-08-01
US12043666B2 (en) 2024-07-23
KR20230123962A (ko) 2023-08-24
AU2021405730A9 (en) 2025-03-20
JP2024500920A (ja) 2024-01-10
US11479610B2 (en) 2022-10-25
WO2022136569A1 (en) 2022-06-30
US20230108007A1 (en) 2023-04-06
US20220242950A1 (en) 2022-08-04
EP4267625A1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US12043666B2 (en) Anti-IL1RAP antibody
US12398213B2 (en) Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies
TWI853077B (zh) 新型抗ｃｄ３９抗體
US10562971B2 (en) Method of detection of IL1RAP on cells expressing the protein
JP2021526022A (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
JP6931750B2 (ja) 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
JP2020501531A (ja) 新規抗ｃｄ１３７抗体およびその使用
JP2019502380A (ja) ＴＮＦ−α、ＩＬ−１７Ａ及びＩＬ−１７Ｆに特異性を有する多重特異性抗体分子
JP2019162119A (ja) Ｉｌ−１７ｃに対する抗体
KR20230110303A (ko) 폴레이트 수용체 알파에 결합하는 중쇄 항체
KR20230166120A (ko) 새로운 tnfr2 결합 분자
JP2020508074A (ja) Ｃｘｃｒ２抗体及びその使用
JP2022522815A (ja) Ｔｓｇ－６抗体およびその用途
CN116724055A (zh) 抗il1rap抗体
KR20260007604A (ko) 항-il1rap 항체
WO2021164722A1 (zh) 抗il-2抗体、其抗原结合片段及其医药用途
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
CN116490519A (zh) 多特异性免疫靶向分子及其用途

Legal Events

Date Code Title Description
SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): CANTARGIA AB